Pierre Johansen

ORCID

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 11

Top Venues

PharmacoEconomics

Advances in therapy

Diabetes, obesity & metabolism

Endocrinology, diabetes & metabolism

Novo Nordisk AS

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Novo Nordisk AS Jun 15 2017

Denmark

Senior Global HEOR Manager :: Global Patient Access

Swedish Institute for Health Economics Jul 23 2015 - Jun 14 2017

Sweden

Research Manager

Publications

Michal Witkowski, Søren Ilsøe Moreno, João Fernandes, Pierre Johansen, Margarida Augusto, Sunita Nair
The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review. PharmacoEconomics 40 (8) (2022)
Mikkel Hasse Pedersen, Mette Bøgelund, Carsten Dirksen, Pierre Johansen, Nils B Jørgensen, Sten Madsbad, Ulrik H Pantin
The prevalence of comorbidities in Danish patients with obesity - A Danish register-based study based on data from 2002 to 2018. Clinical obesity 12 (5) (2022)
Lyndon Marc Evans, Linda Mellbin, Pierre Johansen, Jack Lawson, Abby Paine, Anna Sandberg
A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease. Endocrinology, diabetes & metabolism 4 (3) (2021)
Michael Willis, Adam Fridhammar, Jens Gundgaard, Andreas Nilsson, Pierre Johansen
Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM. PharmacoEconomics 38 (9) (2021)
Sandra Lopes, Pierre Johansen, Mark Lamotte, Phil McEwan, Anamaria-Vera Olivieri, Volker Foos
External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions. PharmacoEconomics 38 (10) (2021)
Pierre Johansen, Daniel Howard, Ryan Bishop, Søren Ilsøe Moreno, Kristine Buchholtz
Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. PharmacoEconomics 38 (5) (2021)
Sofie Persson, Pierre Johansen, Emelie Andersson, Peter Lindgren, Desirée Thielke, Brian Larsen Thorsted, Johan Jendle, Katarina Steen Carlsson
Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden. Diabetes, obesity & metabolism 22 (9) (2020)
Sandra Lopes, Pierre Johansen, Mark Lamotte, Phil McEwan, Anamaria-Vera Olivieri, Volker Foos
Authors' reply to Comment on "External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions". PharmacoEconomics 39 (1) (2020)
Pierre Johansen, Anna Sandberg, Matthew Capehorn
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK. Advances in therapy 37 (3) (2020)
Pierre Johansen, Barrie Chubb, Barnaby Hunt, Samuel J P Malkin, Anna Sandberg, Matthew Capehorn
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK. Advances in therapy 37 (5) (2020)
Michael Willis, Pierre Johansen, Andreas Nilsson, Christian Asseburg
Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). PharmacoEconomics 35 (3) (2017)

Pierre Johansen.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Pierre Johansen